Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Strongbridge will seek accelerated approval for Recorlev after encouraging data, but speed is not the most important factor for success.
Disappointing second-quarter sales of Novo Nordisk's GLP-1 agonists, Victoza and its successor Ozempic, raise questions.
Lower factor expression and immune reactions hand big lead to rival Biomarin.
To lose one lead product may be regarded as a misfortune; to lose two looks like carelessness.
A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.
The Australian group has found a partner for its lead asset at last, so why is the stock down?
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
Smaller transcatheter aortic valve groups face a tricky future.